Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Company News

Company News

On the Eve of Clinical Breakthrough: Zhongjia's Serum-Free hiPSC Medium Sets a New Paradigm

2026-3-18

  A breakthrough year for global iPS medical application, as China’s “medium power” breaks through decisively!

  On March 6, a major approval from Japan’s Ministry of Health, Labour and Welfare rippled through the biomedical sector – two iPS cell-derived regenerative medicine products were officially approved for clinical application: Cuorips’ myocardial cell sheet brings new life to patients with severe heart failure, while Sumitomo Pharma’s dopaminergic neuronal precursor cells light up new hope for Parkinson’s disease treatment. This marks that after 20 years of technical accumulation, the Nobel Prize-level “omnipotent cells” iPS have officially moved from the laboratory to the bedside, and global regenerative medicine has entered a commercial-explosion period!

  Behind this medical revolution lies a core supporting technology – the breakthrough of stem cell culture media. As the “nutritional cornerstone” for cell proliferation and differentiation, the stability and safety of the medium directly determine the success or failure of clinical transformation. Shenzhen Zhongjia Biomedical Technology Co., Ltd., with a serum-free, feeder-free, chemically defined iPS/ES cell-specific medium, is injecting robust strength into China’s research and industry communities, helping accelerate the landing of the “cell healing” dream.

  Three core breakthroughs restructure the iPS cell culture standard
Serum-free + chemically defined, building a clinical safety line
Traditional serum-containing media have complex components and large batch differences, hiding heterologous contamination and immune rejection risks, becoming a “hidden barrier” to clinical transformation. Zhongjia Biomedical’s medium breaks through by removing serum components and using a combination of natural small-molecule compounds (flavanones, syringic acid, etc.) as core additives, not only avoiding the uncertainty caused by serum but also achieving high batch-to-batch reproducibility through precise composition, completely avoiding heterologous rejection risks and providing key guarantees for GMP-grade production of cell therapy products.

  Feeder-free design + no weekend feeding, liberating research productivity
Abandoning the cumbersome traditional process that relies on feeder cells, Zhongjia Biomedical’s medium optimizes the nutritional system so that iPS/ES cells maintain high proliferation activity and multilineage differentiation potential in a feeder-free environment, with cell cloning efficiency and mitochondrial metabolism levels superior to traditional media. The user-friendly design of “no weekend feeding” greatly reduces researchers’ time costs, making the cell culture process more efficient and flexible, suitable for high-throughput research and scale-up production needs.

  Dual cell compatibility + clinical-grade quality, covering all scenarios
Tailored for human embryonic stem cells (ES) and induced pluripotent stem cells (iPS), the product provides stable and reliable nutritional support whether for cell line establishment and disease modeling in basic research, or cell expansion and differentiation induction in clinical transformation. The product has passed dual quality system certifications of ISO 9001:2015 and ISO 13485:2016, and has obtained a Drug Master File (DMF) certification (Number 043469) issued by the U.S. Food and Drug Administration (FDA) – this international authoritative recognition signifies that the product’s manufacturing process and quality control system fully meet the highest global regulatory standards. Customers can directly cite this DMF number when filing FDA clinical or marketing applications, greatly shortening review cycles and reducing filing costs. Supported by Zhongjia Biomedical’s 12,000 square meter GMP pharmaceutical building and 19 core technology patents, product quality reaches an internationally advanced level, providing technical support to nearly a thousand top-tier hospitals and research institutions nationwide, with some products exported overseas.

  Riding the momentum, domestic media lead the global track
Currently, the global iPS cell culture medium market is growing at a rate as high as 14.56%. Leveraging policy support, research breakthroughs and huge market demand, China is becoming the “growth engine” of the global stem cell industry. The approval of two clinical products in Japan further validates the clinical value of iPS technology and brings explosive demand to the medium industry. As a national high-tech enterprise and a “specialized, refined, distinctive and innovative” enterprise, Zhongjia Biomedical, with core principles of “technical excellence and quality safety” and international qualifications such as the FDA DMF certification, breaks the monopoly of international giants, promotes domestic substitution, and helps Chinese cell therapy products go global smoothly.

  From basic research in the laboratory to the final landing of clinical application, Zhongjia Biomedical’s serum-free hiPSC medium, with its core advantages of “defined components, safe and stable, efficient and convenient + international compliance”, is becoming the key bridge connecting research and clinical practice. In this regenerative medicine revolution that concerns human health, Zhongjia Biomedical invites you to join hands – using cells as the brush and technology as the ink, together writing a new chapter of “reshaping the miracle of life”!

  Inquire now: get your exclusive iPS/ES cell culture solution and unlock the password to accelerated clinical transformation.
Official website: https://www.szzjbio.com/

Related News

  • Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?

    2026-10-23

  • Can Alzheimer’s Risk Be Reduced? WHO Guidance Highlights Modifiable Dementia Risk Factors

    2026-9-28

  • Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research

    2026-9-28

  • New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction

    2026-9-28

  • Great News! Another Zhongjia Medium Gets FDA DMF Filing

    2026-7-23